HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Silvio Danese  ¹     Edward V. Loftus Jr  ²     Remo Panaccione  ³     Timothy Hoops  ⁴     Tony Ma  ⁴     Zhijie Ding  ⁴     Erik Muser  ⁴     Christopher Gasink  ⁴     Matthieu Allez  ⁵     William Sandborn  ⁶     James Izanec  ⁶     Peter Irving  ^7    
1 Humanitas Clinical and Research Center, Humanitas University, Milan, Italy
² Mayo Clinic College of Medicine, Rochester, United States
³ University of Calgary, Calgary, Canada
⁴ Janssen Scientific Affairs, LLC, Horsham, United States
⁵ Université de Paris, Paris, France
⁶ University of California San Diego, San Diego, United States
⁷ Guy’s and Saint Thomas’ Hospitals NHS Trust, London, United Kingdom

Session
IBD: Cross-sectional

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)